【摘要】 目的:调查我院初诊2型糖尿病的老年患者常用的三组口服降糖药物治疗方案,进行3个治疗方案的成本-效果分析,并了解低血糖发生比例,为老年患者选择降糖治疗方案提供参考。方法:采用回顾性调查,将我院初诊2型糖尿病的老年患者,均在口服二甲双胍的基础上,A组加用格列美脲,B组加用瑞格列奈,C组加用吡格列酮,采集监测的血糖值和糖化血红蛋白作为效果测量指标,进行成本-效果分析,并统计低血糖发生次数。结果:三组间患者的基本情况比较,差异无统计学意义(P>0.05)。ABC组治疗方案的药物成本均数为675.15元,875.95元,650.15元,3组治疗方案效价比A组大于B、C组,B组和C组之间无统计学差异,A组发生低血糖比例明显大于B、C组。结论:对于2型糖尿病患者的初始治疗,选用格列美脲联合二甲双胍的治疗方案效价比高,但低血糖发生率高。高龄、智能和认知障碍、自理能力差、肝肾功能减退、预计远期寿命较短的患者可选择使用瑞格列奈的治疗方案。更多还原

【Abstract】 Objective To investigate commonly used three oral hypoglycemic drug treatment programs in elderly patients of newly diagnosed type 2 diabetes in our hospital,analyse their cost- effectiveness,and learn hypoglycemia rate,to provide a reference of antidiabetic treatment options for elderly patients. Method Retrospective survey was performed,elderly patients of newly diagnosed type 2 diabetes in our hospital were treated with Glimepiride( Group A),Repaglinide( Group B) and Pioglitazone( Group C),respectively,besides oral metformin. Blood glucose levels and glycated hemoglobin were measurement indicators,cost- effectiveness of three treatment programs were analysed,the number of statistical hypoglycemia was calculated. Results The basic situation was no significant difference among the three groups of patients( P > 0. 05). Average drug costs of Group A,B and C were $ 675. 15,875. 95 and 650. 15,respectively,program A had a higher cost- effectiveness than program B and C,there was no significant difference between program B and C. Hypoglycemia rate in group A was significantly greater than group B,C. Conclusion For the initial treatment of type 2 diabetes,Glimepiride in combination with metformin has a higher cost- effectiveness and hypoglycemia rate. Patients with age,cognitive disorders,poor self- care,liver and kidney dysfunction,expected long- term short- life may use Repaglinide treatment.更多还原